RE: Nigel Burton's Options' exercise - today's RNS15 Feb 2022 19:08
From RNS - https://polaris.brighterir.com/public/microsaic_systems/news/rns/story/xo73mmr (10th Jan 22)
Business model transition from capital instrument sales to complete workflows in Human and Environmental Health, including data analytics
'While equipment sales opportunities still feature for the Company's MS technology and will continue to feature as part of our revenue mix, the Board believes the Company's transition to workflow solution sales will establish higher-level end-user engagement.'
'Progress on this strategy has been made in 2021 contributing to the Company's order increase, particularly in H2 2021, and the Board believes this progress will yield significant gains in 2022.
'Further progress is being made towards driving the value of data through collaborations on software and AI in Environmental Health. This includes both our work with DeepVerge's subsidiary Modern Water, adding portable real-time sewage monitoring, using AI to power analysis for substances such as drugs of abuse and active pharmaceutical ingredients, and our work with Swansea University Medical School looking at the interaction of epigenetics and environmental factors including pollutants. In October, Microsaic launched its services business, providing a suite of solutions that provide the knowledge, applications and services including environmental, bioprocessing optimization and analytics and workflow solutions, and emerging translational medicine. Potential markets span industries including Pharmaceuticals/Biopharmaceuticals, Food Safety, Environmental and Clinical, and this business will further augment the Company's ongoing transition towards offering complete solutions to end-users in Human and Environmental Health.'
Outlook
'The Company has entered 2022 with a healthy sales opportunities pipeline. The Board is targeting a significant increase in revenues in 2022, underpinned by scientific services opportunities, particularly in bioprocessing and water markets, but also the extension of Microsaic's detection platform into Human and Environmental Health real-time monitoring. The Company continues to take a measured approach to market access with a keen focus on expenditure. Microsaic intends to grow its business in conjunction with partners, such as DeepVerge in water detection collaborations, with contract research organisations in bioprocessing, through the extension of its Chinese business with a range of local partners, and via OEM and other strategic partnerships under discussion.'
ATB